Antibodies to Lipids and Liposomes: Immunology and Safety

References

• Alving C. R. Natural antibodies against phospholipids and liposomes in humans. Biochem. Soc. Trans 1984; 12: 342–344, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alving C. R. Antibodies to liposomes, phospholipids, and phosphate esters. Chem. Phys. Lipids 1986; 40: 303–314, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Alving B. M. Lupus anticoagulants, anticardiolipin antibodies, and the antiphospholipid syndrome. Thrombosis and Hemorrhage, J. Loscalzo, A. I. Schafer. Blackwell Schientific Publications, Cambridge 1994; 749–766
   Google Scholar
• Alving C. R. Design and selection of vaccine adjuvants: Animal models and human trials. Vaccine 2002; 20: S56–S64, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Alving C. R., Swartz G. M., Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit. Rev. Immunol 1991; 10: 441–453, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alving C. R., Wassef N. M. Naturally-occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunology Today 1999; 20: 362–366, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Alving C. R., Swartz G. M., Jr., Wassef N. M. Naturally occurring autoantibodies to cholesterol in humans. Biochem. Soc. Trans 1989; 17: 637–639, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alving B. M., Banerji B., Fogler W. E., Alving C. R. Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate. Clin. Exp. Immunol 1987; 69: 403–408, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alving C. R., Swartz G. M., Jr., Wassef N. M. Naturally occurring autoantibodies to cholesterol in humans. Biochem. Soc. Trans 1989; 17: 637–639, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alving C. R., Swartz G. M., Wassef N. M., Ribas J. L., Herderick E. E., Virmani R., Kolodgie F. D., Matyas G. R., Cornhill J. F. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J. Lab. Clin. Med 1996; 127: 40–49, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Avila J. L., Rojas M., Avila A. Cholesterol sulphate-reactive autoantibodies are specifically increased in chronic chagasic human patients. Clin. Exp. Immunol 1996; 103: 40–46, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Arvieux J., Darnige L., Caron C., Reber G., Bensa J. C., Colomb M. G. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb. Haemost 1995; 74: 1120–1125, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Banerji B., Lyon J. A., Alving C. R. Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes. Biochim. Biophys. Acta 1982; 689: 319–326, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bate C. A., Kwiatkowski D. A monoclonal antibody that recognizes phosphatidylinositol inhibits induction of tumor necrosis factor alpha by different strains of Plasmodium falciparum. Infect. Immun 1994; 62: 5261–5266, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bate C. A., Taverne J., Bootsma H. J., Mason R. C., Skalko N., Gregoriadis G., Playfair J. H. Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. Immunology 1992; 76: 35–41, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Batenjany M. M., Boni L. T., Guo Y., Neville M. E., Bansal S., Robb R. J., Popescu M. C. The effect of cholesterol in a liposomal Muc1 vaccine. Biochim. Biophys. Acta 2001; 1514: 280–290, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bowie E. J. W., Thompson J. H., Pascuzzi C. A., Owen C. A., Jr. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J. Lab. Clin. Med 1963; 62: 416–430, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cabiedes J., Cabral A. R., Alarcon-Segovia D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur. J. Immunol 1998; 28: 2108–2114, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Canoso R. T., Sise H. S. Chlorpromazine-induced lupus anticoagulant and associated immunological abnormalities. Am. J. Hematol 1982; 13: 121–129, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Colaco C. B., Male D. K. Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: Distinct profiles of epitope specificity. Clin. Exp. Immunol 1985; 59: 449–456, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Conley C. L., Hartmann R. C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. Clin. Invest 1952; 31: 621–622, [CSA]
   Web of Science ®Google Scholar
• Dijkstra J., Swartz G. M., Jr., Raney J. J, Aniagolu J., Toro L., Nacy C. A., Green S. J. Interaction of anti-cholesterol antibodies with human lipoproteins. J. Immunol 1996; 157: 2006–2013, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fogler W. E., Swartz G. M., Jr., Alving C. R. Antibodies to phospholipids and liposomes: Binding of antibodies to cells. Biochim. Biophys. Acta 1987; 903: 265–272, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Frick P. G. Acquired circulating anticoagulants in systemic “collagen disease.” Auto-immune thromboplastin deficiency. Blood 1955; 10: 691–706, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Fries L. F., Gordon D. M., Richards R. L., Egan J. E., Hollingdale M. R., Gross M., Silverman C., Alving C. R. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 1992; 89: 358–362, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gastineau D. A., Kazmier F. J., Nichols W. L., Bowie E. J. W. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am. J. Hematol 1985; 19: 265–275, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Galli M., Comfurius P., Maassen C., Hemker H. C., de Baets M. H., van Breda-Vriesman P. J., Barbui T., Zwaal R. F., Bevers E. M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Harris E. N., Gharavi A. E., Boey M. L., Patel B. M., Mackworth-Young C. G., Loizou S., Hughes G. R. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211–1214, [CSA], [CROSSREF]
   Google Scholar
• Harris D. T., Matyas G. R., Gomella L. G., Talor E., Winship M. D., Spitler L. E., Mastrangelo M. J. Immunologic approaches to the treatment of prostate cancer. Semin. Oncology 1999; 26: 439–447, [CSA]
   PubMed Web of Science ®Google Scholar
• Heppner D. G., Gordon D. M., Gross M., Wellde B., Leitner W., Krzych U., Schneider I., Wirtz R. A., Richards R. L., Trofa A., Hall T., Sadoff J. C., Boerger P., Alving C. R., Sylvester D. R., Porter T. G., Ballou W. R. Safety, immunogenicity and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis 1996; 174: 361–366, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Horvath A., Biro A. Anti-cholesterol antibodies in human sera. Autoimmun. Rev 2003; 2: 272–277, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Horvath A., Fust G., Horvath I., Vallus G., Duba J., Harcos P., Prohaszka Z., Rajnavolgyi E., Janoskuti L., Kovacs M., Csaszar A., Romics L., Karadi I. Anti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHA. Atherosclerosis 2001; 156: 185–192, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Hughes G. R. V., Harris N. N., Gharavi A. E. The anticardiolipin syndrome. J. Rheumatol 1986; 13: 486–489, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Koscielak J., Hakomori S., Jeanloz R. W. Glycolipid antigen and its antibody. Immunochemistry 1968; 5: 441–455, [CSA], [CROSSREF]
   Google Scholar
• Kostner G. M., Laggner P. Chemical and physical properties of lipoproteins. Human Plasma Lipoproteins, J. C. Fruchart, J. Shepard. Walter deGruyter, Berlin, NY 1989; 23–54
   Google Scholar
• Larsen S. A., Steiner B. M., Rudolph A. H. Laboratory diagnosis and interpretation of tests for syphilis. Clin. Microbiol. Rev 1995; 8: 1–21, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lockshin M. D., Druzin M. L., Goei S., Qamar T., Magid M. S., Jovanovic L., Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with lupus erythematosus. New Eng. J. Med 1985; 313: 152–156, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Male C., Foulon D., Hoogendoorn H., Vegh P., Silverman E., David M., Mitchell L. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 4152–4158, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Matyas G. R., Alving C. R. Protective prophylactic immunity against intranasal ricin challenge induced by liposomal ricin A subunit. Vaccine Res 1996; 5(3)163–172, [CSA]
   Google Scholar
• Matyas G. R., Wassef N. M., Rao M., Alving C. R. Induction and detection of antibodies to squalene. J. Immunol. Methods 2000; 245: 1–14, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Matyas G. R., Rao M., Alving C. R. Induction and detection of antibodies to squalene. II. Optimization of the assay for murine antibodies. J. Immunol. Methods 2002; 267: 119–129, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Matyas G. R., Rao M., Pittman P. R., Burge R., Robbins I. E., Wassef N. M., Thivierge B., Alving C. R. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J. Immunol. Methods 2004; 286: 47–67, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McElrath M. J. Selection of potent immunological adjuvants for vaccine construction. Semin. Cancer Biol 1995; 6: 375–385, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 1990; 87: 4120–3124, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miyakis S., Giannakopoulos B., Krilis S. A. Beta 2 glycoprotein I–function in health and disease. Thromb. Res 2004; 114: 335–346, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Miyakis S., Lockshin M. D., Atsumi T., Branch D. W., Brey R. L., Cervera R., Derksen R. H., De Groot P. G., Koike T., Meroni P. L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P. G., Krilis S. A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost 2006; 4: 295–306, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mueh J. R., Herbst K. D., Rapaport S. I. Thrombosis in patients with lupus anticoagulants. Ann. Int. Med 1980; 92: 156–159, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pierangeli S. S., Goldsmith G. H., Krnic S., Harris E. N. Differences in functional activity of anticardiolipin antibodies from patients with syphilis and those with antiphospholipid syndrome. Infect. Immun 1994; 62: 4081–4084, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Rao M., Bray M., Alving C. R., Jahrling P., Matyas G. R. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4+ T cells. J. Virol 2002; 76: 9176–9185, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rao M., Matyas G. R., VanCott T. C., Birx D. L., Alving C. R. Immunostimulatory CpG motifs induce cytotoxic T lymphocyte responses to human immunodeficiency virus type I oligomeric gp 140 envelope protein. Immunol. Cell Biol 2004; 82: 523–530, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Richards R. L., Rao M., VanCott T. C., Matyas G. R., Birx D. L., Alving C. R. Liposome-stabilized oil-in-water emulsions as adjuvants: increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen. Immunol. Cell Biol 2004; 82: 531–538, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Richardson E. C., Swartz G. M., Jr., Moe J. B., Alving C. R. Life-long administration of liposomes and lipid A in mice: Effects on longevity, antibodies to liposomes, and terminal histopathological patterns. J. Liposome Res 1988–89; 1: 93–110, [CSA]
   Google Scholar
• Samuel J., Budzynski W. A., Reddish M. A., Ding L., Zimmermann G. L., Krantz M. J., Koganty R. R., Longenecker B. M. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int. J. Cancer 1998; 75: 295–302, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schleider M. A., Nachman R. L., Jaffe E. A., Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499–509, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schuster B. G., Neidig M., Alving B. M., Alving C. R. Production of antibodies against phosphocholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J. Immunol 1979; 122: 900–905, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shapiro S. S., Thiagarajan P. Lupus anticoagulants. Prog. Hemostasis Thromb 1982; 6: 263–285, [CSA]
   PubMedGoogle Scholar
• Shichijo S., Alving C. R. Influence of glycolipids on immune reactions of phospholipid antigens in liposomes. Biochim. Biophys. Acta 1985; 820: 289–294, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Swartz G. M., Jr., Gentry M. K., Amende L. M., Blanchette-Mackie E. J., Alving C. R. Antibodies to cholesterol. Proc. Natl. Acad. Sci. U.S.A 1988; 85: 1902–1906, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Thiagarajan P., Shapiro S. S., DeMarco L. Monoclonal immunoglobulin Mx coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J. Clin. Invest 1980; 66: 397–405, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Vaarala O., Palosuo T., Kleemola M., Aho K. Anticardiolipin response in acute infections. Clin. Immunol. Immunopath 1986; 41: 8–15, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Wassef N. M., Roerdink F., Swartz G. M., Jr., Lyon J. A., Berson B. J., Alving C. R. Phosphate-binding specificity of monoclonal antibodies to phosphoinositides in liposomes. Mol. Immunol 1984; 21: 863–868, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wassef N. M., Kim S., Simon M., Alving C. R. Antibodies to acidic phospholipids and lipid A in normal human sera: Complement-dependent damage to liposomes. Clin. Exp. Rhematol 1988; 6: 215, [CSA]
   Google Scholar
• Yin E. T., Gaston L. W. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb. Diath. Haemorrh 1965; 14: 88–115, [CSA]
   PubMedGoogle Scholar